

PUBLICATIONS

1- PUBLICATIONS ORIGINALES

1-1. Internationales

1. **Andremont A.** Tancrede C. Reduction of the aerobic gram-negative bacterial flora of the gastro-intestinal tract and prevention of traveller's diarrhea using oral erythromycin. *Ann. Microbiol. (Inst. Pasteur)* **132B**: 419-427, 1981.
2. Champsaur H., **Andremont A.**, Mathieu D., Rottman E., Auzepy P. Cholera-like illness due to *Aeromonas sobria*. *J. Infect. Dis.* **145**: 248-254, 1982.
3. Goldstein F.W., Kitzis M.D., **Andremont A.O.**, Lambert T.E., and Acar J.F. Comparative *in vitro* evaluation of Sch 29482 a new beta-lactam antibiotic, on enteropathogenic bacteria. *J. Antimicrob. Chemother.* **9**: suppl. c: 159-161, 1982.
4. **Andremont A.**, Raibaud P., Tancrede C. Effect of erythromycin on microbial antagonisms : a study in gnotobiotic mice associated with a human fecal flora. *J. Infect. Dis.* **148**: 579-587, 1983.
5. Tancrede C., **Andremont A.**, and Léonard F. Epidemiology of enterobacteria resistant to Cefotaxime in hospital. *J. Antimicrob. Chemother.* **14**: Suppl. B: 53-57, 1984.
6. **Andremont A.**, Gerbaud G., Tancrede C., Courvalin P. Plasmid-mediated susceptibility to intestinal microbial antagonisms in *Escherichia coli*. *Infect. Immun.* **49**: 751-755, 1985.
7. Léonard F., **Andremont A.**, Tancrede C. *In vivo* activity of nifurzide and nifuroxazide in intestinal bacteria in man and gnotobiotic mice. *J. Appl. Bacteriol.* **58**: 545-553, 1985.
8. Tancrede C.H., **Andremont A.O.** Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. *J. Infect. Dis.* **152**: 99-103, 1985.
9. **Andremont A.**, Gerbaud G., Courvalin C. Plasmid-mediated high-level resistance to erythromycin in *Escherichia coli*. *Antimicrob. Agents Chemother.* **29**: 515-518, 1986.
10. **Andremont A.**, Sancho-Garnier H. and Tancrede C. Epidemiology of intestinal colonization by members of the family *Enterobacteriaceae* highly resistant to erythromycin in a hematology-oncology unit. *Antimicrob. Agents Chemother.* **29**: 1104-1107, 1986.
11. Arthur M., **Andremont A.**, Courvalin P. Heterogeneity of genes conferring high-level resistance to erythromycin by inactivation in enterobacteria. *Ann. Inst. Pasteur/Microbiol.* **137A**: 125-134, 1986.
12. Baruchel A., Hartmann O., **Andremont A.**, Tancrede C. Severe gram-negative infections in neutropenic children cured by imipenem/cilastatin in combination with an aminoglycoside. *J. Antimicrob. Chemother.* **18**: 167-173, 1986.
13. Fontaine O., Ducluzeau R., Raibaud P., Chabanet C., Popoff M.R., Badoual J., Gabilan J.C., **Andremont A.** Comparaison entre le nombre et la nature des *Clostridium* fécaux et d'autres facteurs de risque impliqués dans la pathologie intestinale des nouveau-nés. *Ann. Inst. Pasteur/Microbiol.* **137B**: 61-75, 1986.
14. Pecquet S., **Andremont A.**, Tancrede C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. *Antimicrob. Agents Chemother.* **29**: 1047-1052, 1986.
15. Prévot M.H., **Andremont A.**, Sancho-Garnier H., Tancrede C. Epidemiology of intestinal colonization by members of the family *Enterobacteriaceae* resistant to cefotaxime in a hematology-oncology unit. *Antimicrob. Agents Chemother.* **30**: 945-947, 1986.
16. Arthur M., **Andremont A.**, Courvalin P. Distribution of erythromycin esterase and rRNA methylase genes in members of the family *Enterobacteriaceae* highly resistant to erythromycin. *Antimicrob. Agents Chemother.* **31**: 404-409, 1987.
17. Henry-Michelland S., Alonso M.J., **Andremont A.**, Maincen P., Sauzières J., Couvreur P. Attachment of antibiotics to nanoparticles : preparation, drug-release and antimicrobial activity *in vitro*. *Internat. J. Pharmac.* **35**: 121-127, 1987.
18. Pecquet S., **Andremont A.**, Tancrede C. Effect of oral ofloxacin on fecal bacteria in human volunteers. *Antimicrob. Agents Chemother.* **31**: 124-125, 1987.

19. Weems J.J., **Andremont A.**, Davis B.J., Tancrede C.H., Guiguet M., Padhye A.A., Squinazi F., Martone W.J. Pseudoepidemic of aspergillosis after development of pulmonary infiltrates in a group of bone marrow transplant patients. *J. Clin. Microb.* **25**: 1459-1462, 1987.
20. Youssef M., Cortier G., Goossens H., Tancrede C., Henry-Amar M., **Andremont A.** Comparative translocation of enteropathogenic *Campylobacter spp.* and *Escherichia coli* from the intestinal tract of gnotobiotic mice. *Infect. Immun.* **55**: 1019-1021, 1987.
21. **Andremont A.**, Paulet R., Nitenberg G., and Hill C. Value of semiquantitative cultures of blood drawn through catheter hubs for estimating the risk of catheter tip colonization in cancer patients. *J. Clin. Microbiol.* **26**: 2297-2299, 1988.
22. Karabinis A., Hill C., Leclercq B., Tancrede C., Baume D., **Andremont A.** Risk factors for candidemia in cancer patients : a case-control study. *J. Clin. Microbiol.* **26**: 429-432, 1988.
23. Youssef M., Fattal E., Alonso M.J., Roblot-Treupel L., Sauzières J., Tancrede C., Omnès A., Couvreur P., and **Andremont A.** Effectiveness of nanoparticle-bound ampicillin in the treatment of *Listeria monocytogenes* infection in athymic nude mice. *Antimicrob. Agents Chemother.* **32**: 1204-1207, 1988.
24. **Andremont A.**, Marang B., Tancrede C., Baume D., and Hill C. Antibiotic treatment and intestinal colonization by *Pseudomonas aeruginosa* in cancer patients. *Antimicrob. Agents Chemother.* **33**: 1400-1402, 1989.
25. Aumont P., Enard C., Expert D., Pieddeloup C., Tancrede C., and **Andremont A.** Production of hemolysin, aerobactin and enterobactin, and resistance to human serum in strains of *Escherichia coli* causing bacteremia in cancer patients. *Res. Microbiol.* **140**: 21-26, 1989.
26. Fattal E., Youssef M., Couvreur P., and **Andremont A.** Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. *Antimicrob. Agents Chemother.* **33**: 1540-1543, 1989.
27. Léonard F., **Andremont A.**, Leclercq B., Labia R., and Tancrede C. Use of Beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. *J. Infect. Dis.* **160**: 274-280, 1989.
28. Bougnoux M.E., Hill C., Moissenet D., Feuilhade de Chauvin M., Bonnay M., Vicens-Sprauel I., Pietri F., McNeil M., Kaufman L., Dupouy-Camet J., Bohuon C., and **Andremont A.** Comparison of antibody, antigen and metabolite assays in hospitalized patients with disseminated or peripheral candidiasis. *J. Clin. Microbiol.* **28**: 905-909, 1990.
29. Hill R.R.H., Cowley H.M. and **Andremont A.** Influence of colonizing microflora on the mucin histochemistry of the neonatal mouse colon. *Histochem. J.* **22**: 102-105, 1990.
30. Guiguet M., Rekacewicz C., Leclercq B., Brun Y., Escudier B., **Andremont A.** Effectiveness of simple measures to control an outbreak of nosocomial methicillin-resistant *Staphylococcus aureus* infections in an intensive care unit. *Infect. Control. Hosp. Epidemiol.* **11**: 23-6, 1990.
31. Pecquet S., Ravoire S., and **Andremont A.** Fecal excretion of Ciprofloxacin after administration of a single oral dose and its effect on fecal bacteria in healthy volunteers. *J. Antimicrob. Agents Chemother.* **26**: 125-129, 1990.
32. Richet H., Hubert B., Nitenberg G., **Andremont A.**, Buu-Hoi A., Ourbak P., Galicier C., Veron M., Boisivon A., Bouvier A.M., Ricome J.C., Wolff M.A., Pean Y., Berardi-Grassias L., Bourdain J.L., Hautefort B., Laaban J.P., Tillant D. A prospective multicenter study on vascular catheter-related complications and the risk factors for positive central catheter cultures in ICU patients. *J. Clin. Microbiol.* **28**: 2520-2525, 1990.
33. **Andremont A.**, Tancrede C., and Desnottes J.F. Effect of oral spiramycin on faecal and oral bacteria in human volunteers. *J. Antimicrob. Chemother.* **27**: 355-360, 1991.
34. Chachaty E., Rosebaum M., Tancrede C., and **Andremont A.** Effect of oral Cefotiam Hexetil (SCE 2174) on faecal bacteria in human volunteers. *Microb. Ecol. Health Dis.* **4**: 89-94, 1991.
35. Fattal E., Rojas J., Youssef M., Couvreur P., and **Andremont A.** Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. *Antimicrob. Agents Chemother.* **35**: 770-772, 1991.
36. Fattal A., Rojas J., Roblot-Treupel L., **Andremont A.** and Couvreur P. Ampicillin-loaded liposomes and nanoparticles: comparison of drug loading, drug release and *in vitro* antimicrobial activity. *J. Microencap.* **8**: 29-36, 1991.

37. Pecquet S., Chachaty E., Tancrede C., and **Andremont A.** Effect of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. *Antimicrob. Agents Chemother.* **35**: 548-552, 1991.
38. Pecquet S., Guillaumin D., Tancrede C., and **Andremont A.** Kinetics of *Saccharomyces cerevisiae* elimination from the intestines of human volunteers and effect of this yeast on resistance to microbial colonization in gnotobiotic mice. *Appl. Environ. Microbiol.* **57**: 3049-3051, 1991.
39. Richet H., **Andremont A.**, Tancrede C., Pico J.L., Jarvis W. Risk factors for candidemia in patients with acute lymphocytic leukemia. *Rev. Infect. Dis.* **13**: 211-215, 1991.
40. Valteau D., Hartmann O., Brugières L, Vassal G., Benhamou E., **Andremont A.**, Kalifa C., Lemerle J. Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy. *Bone Marrow Transplant.* **7**: 415-419, 1991.
41. Doucet-Populaire F., Trieu-Cuot P., Dosbaa I., **Andremont A.**, and Courvalin P. Inducible transfer of conjugative transposon Tn1545 from *Enterococcus faecalis* to *Listeria monocytogenes* in the digestive tracts of gnotobiotic mice. *Antimicrob. Agents Chemother* **35**: 185-187, 1991.
42. Chachaty E., Depitre C., Mario N., Bourneix C., Saulnier P., Corthier G. et **Andremont A.** Presence of *Clostridium difficile* and of antibiotic and beta-lactamase activity in the feces of volunteers treated with oral cefixime, oral cefpodoxime (RU51807), or placebo. *Antimicrob. Agents Chemother.* **36**: 2009-2013, 1992.
43. Doucet-Populaire F., Trieu-Cuot P., **Andremont A.**, Courvalin P. Conjugal transfer of plasmid DNA from *Enterococcus faecalis* to *Escherichia coli* in the digestive tract of gnotobiotic mice. *Antimicrob. Agents Chemother.* **36**: 502-504, 1992.
44. Kattan J., Droz J.P., Ribrag V., Azab M., Boutan-Laroze A., **Andremont A.** Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients. *Eur. J. Cancer* **28**: 867-870, 1992.
45. Le Roy D., Expert D., Razafindratsita A., Deroussent A., Cosme J., Bohuon C., and **Andremont A.** Activity and specificity of a mouse monoclonal antibody to ferric aerobactin. *Infect. Immun.* **60**: 768-772, 1992.
46. Saulnier P., and **Andremont A.** Detection of genes in feces by booster polymerase chain reaction. *J. Clin. Microbiol.* **30**: 2080-2083, 1992.
47. Pico J.L., Marie J.P., Chiche D., Guiguet M., **Andremont A.**, Lapierre V., Richet H., Tancrede C., Lagrange P., Hayat M., Zittoun R. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia ? Results of a randomized trial. *Eur. J. Med.* **2**: 275-280, 1993.
48. Saulnier P., Bourneix C., Prévost G., and **Andremont A.** Random amplified polymorphic DNA assay is less discriminant than pulsed-field gel electrophoresis for typing strains of methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* **31**: 982-985, 1993.
49. Le Roy D., Bouchet A., Saulnier P., Pecquet S., and **Andremont A.** Comparison of Chemical Assay, Bioassay, Enzyme-Linked Immunosorbent Assay, and Dot-Blot Hybridization for Detection of Aerobactin in Members of the Family *Enterobacteriaceae*. *Appl. Environ. Microbiol.* **59**: 942-944, 1993.
50. Depitre C., L'Haridon R.M., Lysterly D.M., Barroso L.A., Wilkins T.D., **Andremont A.**, Corthier G. Production of monoclonal antibodies against *Clostridium difficile* cytotoxin using immunosorbent binding bioassay procedure. *Toxicon* **31**: 181-186, 1993.
51. Marty L., Flahaut A., Suarez B., Caillon J. Hill C., and **Andremont A.** Resistance to Methicillin and virulence of *Staphylococcus aureus* in bacteriemic cancer patients. *Intens. Care Med.* **19**: 285-289, 1993.
52. Chachaty E., Bourneix C., Renard S., Bonnay M., and **Andremont A.** Shedding of *Clostridium difficile*, fecal beta-lactamase activity and gastrointestinal symptoms in 51 volunteers treated with oral cefixime. *Antimicrob. Agents Chemother.* **37**: 1437-1435, 1993.
53. Pinto-Alphandary H., Balland O., Laurent M., **Andremont A.**, Puisieux F., and Couvreur P. Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected *in vitro* by *Salmonella typhimurium*. *Pharm. Res.* **11**: 38-46, 1994.
54. Montravers Ph., **Andremont A.**, Massias L., and Carbon C. Investigation of the potential role of *Enterococcus faecalis* in the pathophysiology of experimental peritonitis. *J. Infect. Dis.* **169**: 821-830, 1994.
55. Balland O., Pinto-Alphandary H., Pecquet S., **Andremont A.**, and Couvreur P. The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with *Salmonella typhimurium*. *J. Antimicrob. Chemother.* **33**: 509-522, 1994.

56. Gavaille A., Bardy B., **Andremont A.** Measurement of inhibition zone diameter in disk susceptibility tests by computerized image analysis. *Comput. Biol. Med.* **24**: 179-188, 1994.
57. Bouchet A., Valvano M.A., Dho-Moulin M., Le Roy D., and **Andremont A.** Immunological variants of the aerobactin-cloacin DF13 outer membrane protein receptor IutA among enteric bacteria. *Infect. Immun.* **62**: 3017-3021, 1994.
58. Chachaty E., Saulnier P., Martin A., Mario N. and **Andremont A.** Comparison of ribotyping, pulsed-field gel electrophoresis and random amplified polymorphic DNA for typing *Clostridium difficile* strains. *FEMS Microbiol. Lett.* **122**: 61-68, 1994.
59. Gautheret A., Bourhis J.H., Leclercq B., Guigay J., Piron D., Drommer F., Panelatti G., Tertian G., and **Andremont A.** *Trichoderma pseudokoningii* as a cause of fatal infection in a bone marrow transplant recipient. *Clin. Infect. Dis.* **20**: 1063-1064, 1995.
60. Chachaty E., Youssef M.T., Bourneix C., and **Andremont A.** Shedding of antibiotic resistant members of the family *Enterobacteriaceae* in healthy subjects living in France and in Jordan. *Res. Microbiol.* **146**: 175-182, 1995.
61. Le Roy D., Crouzier Ch., Dho-Moulin M., Dumont A.S., Bouchet A., Lafont J.P., and **Andremont A.** Passive or active immunization directed against ferric aerobactin is not protective in experimental models of enterobacterial infections. *Res. Microbiol.* **146**: 167-174, 1995.
62. Escudier B., Lethiec J.L., Angevin E., **Andremont A.**, Cosset-Delaigue M.F., Antoun S., Leclercq B., Nitenberg G. Totally implanted catheters to reduce catheter-related infection in patients receiving interleukin-2: a 2-year experience. *Sup. Care Cancer* **3**: 297-300, 1995.
63. **Andremont A.**, Lancar R., Lê N.A., Hattchouel J.M., Baron S., Tavakoli F., Daniel M.F., Tancrede C., Lê M.G. Secular trends in morbidity and mortality associated with bloodstream infections in 4,268 patients hospitalized in a cancer referral center between 1975 and 1989. *Clin. Microbiol. Infect.* 1996. *Clin. Microbiol. Infect.* 1996, **1** : 160-167.
64. Barbier N., Saulnier P., Chachaty E., Dumontier S., and **Andremont A.** Random-amplified-polymorphism-DNA (RAPD) versus pulse-field-gel-electrophoresis (PFGE) epidemiological typing of vancomycin-resistant enterococci. *J. Clin. Microbiol.* 1996, **34**: 1096-1099.
65. Balland O., Pinto-Alphandary H., Viron A., Puvion E., **Andremont A.**, Couvreur P. Intracellular distribution of ampicillin in murine macrophages infected with *Salmonella typhimurium* and treated with (³H)ampicillin-loaded nanoparticles. *J. Antimicrob. Chemother.* **37**: 105-115, 1996.
66. Escudier B., Lethiec J.L., Angevin E., **Andremont A.**, Cosset-Delaigue M.F., Antoun S., Leclercq B., Nitenberg G. Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience. *Support Care Cancer* 1995, **3**: 297-300.
67. Balland O., Pinto-Alphandary H., Viron A., Puvion E., **Andremont A.**, and P. Couvreur. Intracellular distribution of ampicillin in murine macrophages infected with *Salmonella typhimurium* and treated with (³H)ampicillin-loaded nanoparticles. *J. Antimicrob. Chemother.* 1996, **37**: 105-115.
68. **Andremont A.**, Lancar R., Lê N.A., Hattchouel J.M., Baron S., Tavakoli F., Daniel M.F., Tancrede C., Lê M.G. Secular trends in mortality associated with bloodstream infections in 4268 patients hospitalized in a cancer referral center between 1975 and 1989. *Clin. Microbiol. Infect.* 1996, **1** : 160-167.
69. Barbier N., Saulnier P., Chachaty E., Dumontier S., and **Andremont A.** Random-amplified-polymorphic-DNA (RAPD) typing versus pulsed-field-gel electrophoresis for epidemiological typing of vancomycin-resistant enterococci. *J. Clin. Microbiol.* 1996, **34**: 1096-1099.
70. Page M.E., Pinto-Alphandary H., Chachaty E., **Andremont A.**, and Couvreur P. Entrapment of colistin into polyhexylcyanoacrylate nanoparticles: preparation, drug release and tissue distribution in mice. *S.T.P. Pharma Sciences* 1996, **6**: 298-301.
71. Moulin F., Dumontier S., Saulnier P., Loubeyre C., Chachaty E., Brugières L., and **Andremont A.** Surveillance of intestinal colonisation and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. *Clin. Microbiol. Infect.* 1996, **2**, n°3, 192-201.
72. Allaoui-Attarki K., Pecquet S., Fattal E., Chachaty E., Couvreur P., and **Andremont A.** Protective immunity against *S.typhimurium* elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-Lactide-Co-Glycolide) microspheres. *Infection and Immunity*, 1997, **65** (3), 853-857.

73. Farida H., P. Saulnier, E. Chachaty, and **A. Andremont**. Decontamination of Polymerase chain reaction reagents for detection of low concentrations of 16S rRNA genes. *Molecular Biotechnology* 1997, **7**, 207-216.
74. Bosne-David SCM, Bricard L, Ramiandrasoa F, Déroussent A, Kunesch G, **Andremont A**. Evaluation of growth promotion and inhibition from mycobactins and non-mycobacterial siderophores (desferoxamine and FR 160) in *Mycobacterium aurum*. *Antimicrobial Agents and Chemotherapy*, 1997, **41** : 1837-1839.
75. Blot F, Schmidt E, Nitenberg G, Tancrede C, Leclercq B, Laplanche A, **Andremont A**. Earlier positivity of central versus peripheral blood cultures is highly predictive of catheter-related bacteremia. *Journal of Clinical Microbiology*. 1998 , **36** : 105-109.
76. T. Tursz, A. Lecesne, P. Baldeyrou, E. Gautier, P. Opolon, C. Schatz, A. Pavirani, M. Courtney, D. Lamy, T. Ragot, P. Saulnier, **A. Andremont**, R. Monier, M. Perricaudet and T. Lechevalier. Recombinant adenoviral-mediated gene transfer : preliminary report of a phase I study in lung cancer patients. *Journal of the National Cancer Institute*, 1996, **88**: 1857-1863.
77. Hilali F., P. Saulnier, E. Chachaty, and **A. Andremont**. Decontamination of Polymerase chain reaction reagents for detection of low concentrations of 16S rRNA genes. *Molecular Biotechnology*, 1997, **7**, 207-216.
78. Saulnier P., Chachaty E., Hilali F., and **Andremont A**. Single step polymerase chain reaction for combined gene detection and epidemiological typing in three bacterial models. *FEMS Microbiology Letters*, 1997, **150**, 311-316.
79. Allaoui-Attarki K, Fattal E, Peckquet S, Trollé S, Chachaty E, Couvreur P, **Andremont A**. Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-Lactide-Co-Glycolide) microspheres. *Vaccine*, 1998, **16** : 685-691.
80. Youssef M., Shurman A., Chachaty E., Bsoul A.R., and **Andremont A**. Use of molecular typing to investigate bacterial translocation from the gastrointestinal tract in malnourished children with Gram-negative bacteremia. *Clinical Microbiology and Infection*, 1998, **4** : 70-74.
81. Page-Clisson ME, Pinto-Alphandary H, Chachaty E, Couvreur P, **Andremont A**. Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent salmonella. *Pharmaceutical Research*, 1998, **15** : 542-547.
82. Blot F, Schmidt E, Nitenberg G, Tancrede C, Leclercq B, Laplanche A, **Andremont A**. Earlier positivity of central versus peripheral blood cultures is highly predictive of catheter-related bacteremia. *Journal of Clinical Microbiology*. 1998 , **36** : 105-109.
83. Poras H., Kunesch G., Barrière J.C., Berthaud N., **Andremont A**. Synthesis and *in vitro* antibacterial activity of catechol-spiramycin conjugates. *The Journal of Antibiotics*, 1998, **51** : 786-794.
84. Page-Clisson M., Pinto-Alphandary H., Ourevitch M., **Andremont A.**, Couvreur P. Development of ciprofloxacin-loaded nanoparticles : physicochemical study of the drug carrier. *J. Controlled Release*, 1998, **56**, 23-32.
85. Marie J.P., Vekhoff A., Pico J.L., Guy H., **Andremont A.**, and Richet H. Neutropenic infections: A review of the French Cooperative febrile aplasia study group trials on 607 febrile episodes. *J. Antimicrob. Chemother.* 1998, **41** (Suppl. D) : 57-64.
86. Infuso A., de Valk H., Bigot-Marie C., Fournier JM., Cadiot G., **Andremont A.**, Desenclos JC. Cholera in a Paris resident with no history of travel. A case report. *Presse Med.*, 1998 , **27** : 202-204.
87. Youssef MT., Malkawi HI., Shurman AA., **Andremont AO**. Molecular typing of multiresistant *Klebsiella pneumoniae* isolated from children from northern Jordan. *J. Trop. Pediatr.*, 1999, **45** : 271-277.
88. Lelièvre H., Lina G., Jones ME., Olive C., Forey F., Roussel-Delvallez M., Nicolas-Chanoine MH., Bebear MC., Jarlier V., **Andremont A.**, Vandenesch F., Etienne J. Emergence and spread in French hospitals of methicillin-resistant *Staphylococcus aureus* with increasing susceptibility to gentamicin and other antibiotics. *J. Clin. Microbiol.*, 1999, **37** : 3452-3457.
89. Trollé S., Caudron E., Léo E., Couvreur P., **Andremont A.**, Fattal E. *In vivo* fate and immune pulmonary response after nasal administration of microspheres loaded with phosphorylcholine-thyroglobulin. *Int. J. Pharm.*, 1999, **183** : 73-79.
90. Hayem G., Kassis N., Nicaise P., Bouvet P., **Andremont A.**, Labarre C., Kahn MF. Systemic lupus erythematosus-associated catastrophic antiphospholipid syndrom occurring after typhoid fever : a possible

role of Salmonella lipopolysaccharide in the occurrence of diffuse vasculopathy-coagulopathy. *Arthritis Rheum.*, 1999, **42** : 1056-1061.

91. Pinto-Alphandary H., **Andremont A.**, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles : research and applications. *International Journal of Antimicrobial Agents*, 2000, **13** : 155-168.
92. Hilali F., Ruimy R., Saulnier P., Barnabe C., Lebouguenec C., Tibayrenc M., **Andremont A.** Prevalence of virulence genes and clonality in *Escherichia coli* strains that cause bacteremia in cancer patients. *Infect. Immun.*, 2000, **68** : 3983-3989.
93. Trollé S., Chachaty E., Kassis-Chikhani N., Wang C., Fattal E., Couvreur P., Diamond B., Alonso J., **Andremont A.** Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with *Streptococcus pneumoniae*. *Vaccine*, 2000, **18** : 2991-2998.
94. **Andremont A.** Environmental factors (antibiotics in animals, day care centers, etc...) *Rev Pneumol Clin*. 2000 Oct;Suppl 1:1S7-8. French.
95. Ruimy R., Genauzeau E., Barnabé C., Beaulieu A., Tibayrenc M., **Andremont A.** and The *P.aeruginosa* Study Group. Genetic diversity of *Pseudomonas aeruginosa* strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water. *Infect. Immun.*, 2001.
96. **Andremont A.**, Brun-Buisson C., Struelens M. Evaluating and predicting the ecologic impact of antibiotics. *Clin Microbiol Infect*. 2001;7 Suppl 5:1-6.
97. Le Bouguenec C., Lalioui L., du Merle L., Jouve M., Courcoux P., Bouzari S., Selvanagan R., Nowicki BJ., Germani Y., **Andremont A.**, Gounon P., Garcia MI. Characterization of AfaE adhesins produced by extraintestinal and intestinal human *Escherichia coli* isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens. *J Clin Microbiol*. 2001 May;39(5):1738-45.
98. Scanvic A., Denic L., Gaillon S., Giry P., **Andremont A.**, Lucet JC. Duration of colonization by methicillin-resistant *Staphylococcus aureus* after hospital discharge and risk factors for prolonged carriage. *Clin Infect Dis*. 2001 May 15;32(10):1393-8.
99. **Andremont A.** The future control of bacterial resistance to antimicrobial agents. *Am J Infect Control*. 2001 Aug;29(4):256-8.
100. Muller-Serieys C., Soler P., Cantalloube C., Lemaître F., Gia HP., Brunner F., **Andremont A.** Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). *Antimicrob Agents Chemother*. 2001 Nov;45(11):3104-8.
101. Denamur E., Bonacorsi S., Giraud A., Duriez P., Hilali F., Amorin C., Bingen E., **Andremont A.**, Picard B., Taddei F., Matic I. High frequency of mutator strains among human uropathogenic *Escherichia coli* isolates. *J Bacteriol*. 2002 Jan;184(2):605-9.
102. Scanvic-Hameg A., Chachaty E., Rey J., Pousson C., Ouzoux ML., Brunel E., **Andremont A.** Impact of quinupristin/dalfopristin (RP59500) on the faecal microflora in healthy volunteers. *J Antimicrob Chemother*. 2002 Jan;49(1):135-9.
103. Lucet JC., Rigaud MP., Mentre F., Kassis N., Deblangy C., **Andremont A.**, Bouvet E. Hand contamination before and after different hand hygiene techniques: a randomized clinical trial. *J Hosp Infect*. 2002 Apr;50(4):276-80.
104. Richet H., Roux P., Des Champs C., Esnault Y., **Andremont A.** Candidemia in French hospitals: incidence rates and characteristics. *Clin Microbiol Infect*. 2002 Jul;8(7):405-12.
105. Fattal E., Pecquet S., Couvreur P., **Andremont A.** Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. *Int J Pharm*. 2002 Aug 21;242(1-2):15-24.
106. Crémieux AC., Muller-Serieys C., Panhard X., Delatour F., Tchimichkian M., Mentré F., **Andremont A.** Emergence of resistance in normal human commensal flora during telithromycin and amoxicillin/clavulanic acid treatments : the invisible collateral damage. *Antimicrob. Agents Chemother.*, 2003, **47** : 2030
107. Brigger, I., Armand-Lefevre, L., Chaminade, P., Besnard, M., Rigaldie, Y., Largeteau, A., **Andremont, A.**, Grislain, L., Demazeau, G. and Couvreur, P. (2003) The stenyling effect of high hydrostatic pressure on thermally and hydrolytically labile nanosized carriers. *Pharm Res*, 2003, **20** : 674-683.
108. **Andremont, A.** (2003) Commensal flora may play key role in sprading antibiotic resistance. *ASM News* 69, 601-607.

109. [Cabrol S, Olliver A, Pier GB, **Andremont A, Ruimy R**](#). Transcription of quorum-sensing system genes in clinical and environmental isolates of *Pseudomonas aeruginosa*. *J Bacteriol.* 2003, **185** :7222-30.
110. [Soussy CJ, Nguyen J, Goldstein F, Dabernat H, **Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P**](#). *In vitro* antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. *Clin Microbiol Infect.* 2003, **9** :997-1005.
111. [Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snyderman DR, Ip M, Ko WC, Chedid MB, **Andremont A, Klugman KP; International Pneumococcal Study Group**](#). An international prospective study of pneumococcal bacteremia: correlation with *in vitro* resistance, antibiotics administered, and clinical outcome. *Clin Infect Dis.* 2003, **37** :230-7.
112. [Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, **Andremont A**](#). Acquisition of multidrug-resistant *Pseudomonas aeruginosa* in patients in intensive care units: role of antibiotics with antipseudomonal activity. *Clin Infect Dis.* 2004 Mar 1;38(5):670-7.
113. Aubry-Damon H., Grenet K., Sall-Ndiaye P., Che D., Cordeiro E., Bougnoux ME., Rigaud E., Yann Le Strat Y., Lemanissier V., Armand-Lefèvre L., Delzescaux D., Desenclos JC., Liénard M., and **Andremont A**. Antimicrobial resistance in commensal flora of pig farmers. *Emerging Infectious Diseases*, 2004, **10** : 873-879.
114. Ruimy R., **Andremont A**. Quorum sensing chez *Pseudomonas aeruginosa* : mécanisme moléculaire, impact clinique, et inhibition. *Réanimation*, 2004, **13** : 176-184.
115. Grenet, K., Guillemot, D., Jarlier, V., Moreau, B., Dubourdieu, S., Ruimy, R., Armand-Lefevre, L., Bau, P. and **Andremont, A**. Antibacterial resistance, Wayampi Amerindians, French Guyana. *Emerg Infect Dis*, 2004, **10** : 1150-1153.
116. Escobar-Paramo, P., Grenet, K., Le Menac'h, A., Rode, L., Salgado, E., Amorin, C., Gouriou, S., Picard, B., Rahimy, M.C., **Andremont, A.**, Denamur, E. and Ruimy, R. Large-Scale Population Structure of Human Commensal *Escherichia coli* Isolates. *Appl Environ Microbiol*, 2004, **70** : 5698-5700.
117. Baddour, L.M., Yu, V.L., Klugman, K.P., Feldman, C., Ortqvist, A., Rello, J., Morris, A.J., Luna, C.M., Snyderman, D.R., Ko, W.C., Chedid, M.B., Hui, D.S., **Andremont, A.** and Chiou, C.C. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. *Am J Respir Crit Care Med*, 2004, **170** :440-444.
118. [Andremont A, Cohen R, Drugeon H](#). How can antibiotics' capacity of selecting bacterial resistance be assessed? *Med Mal Infect.* 2004 Jun; **34**(Suppl 1):S109-S111.
119. Armand-Lefevre L, Ruimy R, **Andremont A**. Clonal Comparison of *Staphylococcus aureus* isolates from healthy pig farmers, human controls, and pigs. *Emerg Infect Dis* 2005, **5** :711-4.
120. [Lucet JC, Grenet K, Armand-Lefevre L, Harnal M, Bouvet E, Regnier B, **Andremont A**](#). High prevalence of carriage of methicillin-resistant *Staphylococcus aureus* at hospital admission in elderly patients: implications for infection control strategies. *Infect Control Hosp Epidemiol.* 2005 Feb ; **26** :121-6.
121. L. Armand-Lefevre, R. Ruimy, **A. Andremont**. Clonal comparison of *Staphylococcus aureus* isolates from healthy pig farmers, human controls, and pigs. *Emerg. Inf. Dis* 2005, **11** : 711-714.
122. R. Ruimy, L. Armand-Lefevre, **A. Andremont**. Short time to positiveness is highly predictive of *Staphylococcus aureus* in blood culture with clustered Gram-positive cocci on direct smear examination. *Am J Infect Control*, 2005, **33** : 304-306.
123. Skurnik D, Le Menac'h A, Zurakowski D, Mazel D, Courvalin P, Denamur E, **Andremont A**, Ruimy R. Integron-associated antibiotic resistance and phylogenetic groups in *Escherichia coli* from healthy subjects free of recent antibiotic exposure. *Antimicrob Agents Chemother* 2005 ; 49 (7) : 3062-65..
124. Bourgeois S, Laham A, Besnard M, **Andremont A**, Fattal E. *In vitro* and *in vivo* evaluation of pectin beads for the colon delivery of beta-lactamases. *J Drug Target.* 2005 ; 13(5):277-84.
125. Aslangul E, Ruimy R, Chau F, Garry L, **Andremont A**, Fantin B. Relationship between the Level of Acquired Resistance to Gentamicin and Synergism with Amoxicillin in *Enterococcus faecalis*. *Antimicrob Agents Chemother.* 2005 ; 49(10):4144-8.
126. Lucet JC, Paoletti X, Lolom I, Paugam-Burtz C, Trouillet JL, Timsit JF, Deblangy C, **Andremont A**, Regnier B. Successful long-term program for controlling methicillin-resistant *Staphylococcus aureus* in intensive care units. *Intensive Care Med.* 2005 ; 31(8):1051-7.

1-2. Nationales

1. Rolland J.C., Lebranchu Y., Gold F., **Andremont A.**, Robert M., Grenier B. Hypertension portale après cathétérisme veineux ombilical. (A propos de 5 observations). *Ouest Médical* **30**: 1639-1642, 1977.
2. Tancrede C., **Andremont A.**, Guerlin N. Effet de l'érythromycine sur les populations d'entérobactéries du tube digestif chez l'homme. *Nouv. Presse Méd.* **9**: 2742-2743, 1980.
3. May-Levin F., Caillou B., **Andremont A.**, Travagli J.P., Vilde J.L. Lymphadénopathies diffuses et persistantes avec infections opportunistes chez un homosexuel. *Nouv. Presse Méd.* **12**: 960, 1983.
4. Tancrede C., **Andremont A.** Bactériémies d'origine intestinale chez les leucémiques en aplasie. *Méd. Mal. Infect.* **5**: 214-219, 1985.
5. Obrecht O., Bouvet E., Saout C., **Andremont A.**, Perrin J. et Kermorvant M. Etude sur la prévention des maladies transmissibles au cours des voyages - (I). *Bull. Epidémiol. Hebdo.* **49**: 193-195, 1987.
6. Obrecht O., Bouvet E., Saout C., **Andremont A.**, Perrin J., Kermorvant M., Prévot M.H. Enquête sur la prévention des maladies transmissibles au cours des voyages - (II). *Bull. Epidémiol. Hebdo.* **50**: 197-198, 1987.
7. Weems J.J., **Andremont A.**, Davis B.J., Tancrede C.H., Guignet M., Padhye A.A., Squinazi F. and Martone W.J. Pseudo-épidémie d'aspergillose chez des greffés de moelle ayant un infiltrat pulmonaire. *Bull. Epidémiol. Hebdo.* **52**: 205-206, 1987.
8. Gajdos Ph., Vercken J.B., Charpak Y., **Andremont A.**, Brun-Buisson C., Carlet J., Raphael J.C., Schlemmer B., Tenaillon A., Thaler F. Etude de la concordance de l'antibiothérapie de première intention au cours des pneumopathies primitives admises en réanimation. *Réan. Soins Intens. Méd. Urg.* **4**: 67-72, 1988.
9. Marie J.P., Pico J., Lapierre V., Maulard C., Pappo M., Chiche D., **Andremont A.**, Lagrange Ph., Hayat M. et Zittoun R. Traitement empirique des épisodes fébriles survenant chez les patients cancéreux présentant une neutropénie prolongée: essai comparatif ceftazidime seule, ceftazidime + amikacine et ceftazidime + vancomycine. *Méd. Mal. Infect.* **21**: 386-388, 1991.
10. Kattan J., Droz J.P., Culine S., Ribrag V., Boutan-Laroze A., **Andremont A.** Intérêt de l'association Pipéracilline-Péfloxaciné suivie éventuellement par la vancomycine dans le traitement des neutropénies fébriles au cours des chimiothérapies néphrotoxiques. *Bull. Cancer* **79**: 705-712, 1992.
11. Marie J.P., Lapierre V., Pico J., Vekhoff A., Molina L., **Andremont A.**, Basset D., Lebeau B., Michalet M., Zittoun R. et Hayat M. Etude multicentrique randomisée fluconazole IV versus amphotéricine B IV chez le patient neutropénique et fébrile. *Cah. Oncol.* **2**: 171-173, 1993.
12. Infuso A, de Valk H, Bigot-Marie C, Fournier JM, Cadiot G, **Andremont A**, Desenclos JC. A propos d'un cas de choléra autochtone à Paris. *La Presse Médicale*, 1998, **27** : 202-204.

2- ARTICLES DIDACTIQUES

1. **Andremont A.** Expliquez-moi... Acquisitions récentes sur l'étiologie des diarrhées aiguës infectieuses de l'enfant : Aspects théoriques et conséquences pratiques. *Rev. Méd. Tours* **10**: 1315-1320, 1976.
2. Grenier B., **Andremont A.**, Bardie F. Diarrhées aiguës à *Escherichia coli*. Développements récents et perspectives. *Nouv. Presse Méd.* **5**: 2241-2244, 1976.
3. Bougnoux Ph., **Andremont A.**, Le Floch O. Bactériémies et aplasies. *Rev. Méd. Tours* **14**: 1029-1034, 1980.
4. **Andremont A.**, Tancrede C. "*Clostridium*" et pathologie digestive (Botulisme exclu). *Encycl. Méd. Chir. Paris, Mal. Infect.* 8038 H20, 5-1981.
5. **Andremont A.** La diarrhée des voyageurs. *Rev. Sciences Méd.* **249**: 45-51, 1983.
6. **Andremont A.**, André P. La diarrhée des voyageurs. *Gaz. Méd. France* **89**: 2493-2496, 1983.
7. Tancrede C., **Andremont A.**, and Léonard F. Epidemiology of enterobacteria resistant to Cefotaxime in hospital. *J. Antimicrob. Chemother.* **14** (Suppl. B): 53-57, 1984.
8. **Andremont A.**, André P. Orientation diagnostique et traitement spécifique des diarrhées aiguës bactériennes (en dehors du choléra et des salmonelloses). *Rev. Prat.* **32**: 1043-1050, 1982.
9. **Andremont A.** Infections sur matériel d'infusion parentérale prolongée. *Méd. Mal. Infect., Spécial Mai*, 323-325, 1987.

10. **Andremont A.** β -lactamines et modifications de la flore fécale. *Méd. Mal. Inf.* **18** (n° hors série): 63-65, 1988.
11. **Andremont A.** La décontamination sélective du tube digestif. *J. Pharm. Clin.* **7**: 145-146, 1988.
12. **Andremont A.** Quelques fonctions et rôle de la flore colique de l'homme. *Gaz. Méd.* **95**: 21-25, 1988.
13. **Andremont A.** Décontamination oropharyngée et digestive: Base théorique, méthodes, adaptation de ces méthodes à la réanimation. In: *Réanimation et Médecine d'Urgence. Expansion Scientifique Française*, 1988, pp. 226-231.
14. **Andremont A.** Erythromycine et écologie des entérobactéries du tube digestif de l'homme. Nécessité d'une approche multidisciplinaire. *Méd. Mal. Infect.* **18** (n° hors série): 21-23, 1988.
15. **Andremont A.** Candida in the gastrointestinal tract: from colonization to disease. Royal Society of Medicine Services International Congress and Symposium Series n° 153, 1989.
16. **Andremont A.** Intérêt des modèles expérimentaux pour l'étude de l'impact des antibiotiques sur la flore intestinale. *Méd. Mal. Infect.* **19**: 691-693, 1989.
17. **Andremont A.** Ecosystème intestinal et antibiothérapie. *La Lettre de l'Infectiologue* **5**: 100-103, 1990.
18. Nitenberg G., Leclercq B., Antoun S., Escudier A., **Andremont A.** Infections à staphylocoques coagulase-négatifs liées aux cathétérismes veineux. *Méd. Mal. Infect.* **3**: 62-72, 1990.
19. **Andremont A.** Bactéries intestinales et infections nosocomiales. *Communications Partenaires Santé* 1991, 178-179.
20. Delouis C., Bultingaire N., **Andremont A.** Diarrhées aiguës. Examens de laboratoire et conséquences thérapeutiques. *Gaz. Méd.* 1991, **98**: 33-41.
21. Couvreur P., Fattal E., and **Andremont A.** Liposomes and nanoparticles in the treatment of intracellular bacterial infections. *Pharm. Res.* 1991, **8**: 1079-1086.
22. **Andremont A.** Epidémiologie et diagnostic indirect des infections à levures en cancérologie. *J. Mycol. Méd.* 1991, **1**: 2-3.
23. Couvreur P., Fattal E., Alphandary H., Puisieux F. and **Andremont A.** Intracellular targeting of antibiotics by means of biodegradable nanoparticles. *J. Controlled Release* 1992, **19**: 259-268.
24. Fattal E., Balland O., Alphandary H., Pecquet S., Puisieux F., Couvreur P., **Andremont A.** Colloidal carriers of antibiotics as an alternating approach for the treatment of intracellular infections. *CRC Press*, 1992.
25. Couvreur P., Fattal E., **Andremont A.** Vectorisation de médicaments antiinfectieux. *Actual. Chim. Thé.* 1992, 19ème série, 167-179.
26. Fattal E., **Andremont A.**, Couvreur P. Les vecteurs colloïdaux d'antibiotiques: Une approche alternative pour le traitement des infections intracellulaires. *La Lettre de l'Infectiologue* 1992, **6**: 223-227.
27. **Andremont A.** L'interdisciplinarité est un plaisir. *Plein Sud*, 1993, **10**: 3-4.
28. **Andremont A.** Antibiotiques. Données générales sur les modes d'action et les mécanismes de résistance. *Rev. Prat. (Paris)* 1993, **19**: 2545-2550.
29. **Andremont A.** La thèse: un outil pédagogique anticrise. *Le Monde de l'Education Déc.* 1993, 12-13.
30. **Andremont A.** Marqueurs épidémiologiques des bactéries hospitalières. In *Infection nosocomiale et résistance aux antibiotiques: évolution et tendances. Journées de l'Hôpital Claude-Bernard, Arnette* 1993, 49-53.
31. **Andremont A.** Infections nosocomiales, écosystème intestinal et spectre d'activité des antibiotiques. *La Lettre Hospitalière* 1994, **7**: 4-7.
32. Cordonnier C., Leverger G., Schlemmer B., **Andremont A.**, Boasson M., Herbrecht R., Karmierczak A., Marie J.P., Marit G., Miclea J.M. Stratégie antibiotique dans les épisodes fébriles au cours des neutropénies profondes (inférieures à 500 PNN) et prolongées (supérieures ou égales à 7 jours). *Nouv. Rev. Fr. Hématol.* 1994, **36**: 289-291.
33. **Andremont A.** Ecosystème Bactérien du tube digestif. Rapports avec le traitement des péritonites. *Méd. Mal. Infect.* 1995, **25** Spécial: 38-41.
34. Saulnier P., **Andremont A.** Les marqueurs moléculaires chez *Staphylococcus aureus* résistants à la Méthicilline. *Annales Institut Pasteur Paris*, 1995, **144**: 5-7.
35. **Andremont A.**, Corpet D. Colonisation intestinale par les bactéries résistantes aux antibiotiques. *Encyclopédie Médico-Chirurgicale*, 1996, 8-001-A-10, 1-5.

36. Saulnier P. et **Andremont A.** Les marqueurs moléculaires chez *Staphylococcus aureus* résistants à la Méthicilline. Annales Institut Pasteur, Paris, 1995, **144**: 5-7.
37. **Andremont A.** Ecosystème Bactérien du tube digestif. Rapports avec le traitement des péritonites. Méd. Mal. Infect. 1995, **25** Spécial: 38-41.
38. Cordonnier C., **Andremont A.**, Boiron P., Ghanassia J.P., Herbrecht R., Leclercq R., Leverger G., Milpied N., Nitenberg G., Rozembaum M., Schlemmer B., Buzin-Veil A., Weinbreck P. Réflexions sur la prophylaxie de l'aspergillose en onco-hématologie. Hématologie, 1996, **2**, n°3, 262-266.
39. **Andremont A.** Un exemple de résistance liée à la pression de sélection à l'hôpital: l'entérocoque. pp. 41-49. Journée de Pharmacologie Clinique - Journée de l'Hôpital Claude Bernard, 1996, Arnette Blackwell, Paris.
40. **Andremont A.** Résistance aux antibiotiques et bactéries du tube digestif. Cahiers Houdé de Gastro-Entérologie : Germes, virus et bactéries. 1996, pp. 18-21.
41. **Andremont A.**, Fressange C. Problèmes spécifiques posés par la résistance aux glycopeptides chez les cocci à Gram positif. La Lettre de l'Infectiologie, 1996, Hors série de Novembre, **XI**, 12-15.
42. **Andremont A.**, Corpet D. Colonisation intestinale par les bactéries résistantes aux antibiotiques. Encyclopédie Médico-Chirurgicale, 1996, 8-001-A-10, 1-5.
43. **Andremont A.**, Corpet D, Courvalin P. La résistance des bactéries aux antibiotiques. Pour la Science, Fev. 1997, n° 232, 66-73.
44. Saulnier P., **Andremont A.** Les marqueurs moléculaires chez *Staphylococcus aureus* résistants à la méticilline. Analyse critique. Médecine et Maladies Infectieuses, 1997, **27** (spécial), 159-164.
45. **Andremont A.** Définition de la multirésistance bactérienne. Prévalence et incidence des bactéries multirésistantes en réanimation. Impact écologique. Réanimation Urgences, 1997, **6** (2 bis) : 175-182.
46. **Andremont A.** Impact écologique de l'antibiothérapie. Communication Partenaires Santé, 1997, 44-47.
47. **Andremont A.** et Corpet D. Rôle du tube digestif de l'homme et des animaux dans la dissémination de la résistance bactérienne aux antibiotiques. GRAM, 1997 (Décembre), n°3, 13-18.
48. **Andremont A.** L'impact des β -lactamines sur la flore intestinale : écologie et économie. Pyrexie, 1998, **2** (n° 5) : 173-178.
49. Aubry-Damon H., **Andremont A.** La surveillance s'organise. La Recherche, 1998, n° 314, 54-55.
50. **Andremont A.**, Duval X. Diarrhée aiguë : quand demander des examens complémentaires ? Le Quotidien du Médecin, 4 Novembre 1998.
51. Trollé S., **Andremont A.**, Fattal E. Towards a multipurpose mucosal vaccination using phosphorylcholine as a unique antigen ? S.T.P Pharma Sciences, 1998, **8** : 19-30.
52. **Andremont A.** Impact des céphalosporines récentes sur l'écosystème intestinal : le cas de céfépime. Antibiotiques, 1999, **1** : 171-175.
53. Chachaty E. et **Andremont A.** Impact de l'antibiothérapie sur l'écologie microbienne en hématologie et en oncologie. Hématologie, numéro spécial, **6**, Janv. 2000, 26-28.
54. **Andremont A.** Consequences of antibiotic therapy to the intestinal ecosystem. Ann. Fr. Anesth. Reanim., 2000, **19** : 395-402.
55. Ruimy R, Genauzeau E, Barnabé C, Beaulieu A, Tibayrenc M, **Andremont A** for the *P. aeruginosa* study group. Genetic diversity of *Pseudomonas aeruginosa* strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water. Infection and Immunity, 2001, **69** : 584-588.
56. **Andremont A.** et Fantin B. Résistance Bactérienne *in vivo* : Emergence et conséquences thérapeutiques. ARET-Actualités, septembre 2002, 6-9